Another report from yet another study has many Americans beginning to feel the stress of COVID overload. However, this one isn’t from the Biden White House, the CDC, or Anthony Fauci. This time it’s from Reuters.
According to Reuters News the effectiveness of one of the three major vaccines currently on the market may not protect those individuals as well as the other two. The culprit in question is the Moderna vaccine which has proven to be less effective in maintaining its overall potency against the COVID virus.
In a recent a conference call with Reuters News, Moderna President Stephen Hoge acknowledged that the vaccine is most effective in the first six months but may begin to lose potency after a year.
Effectiveness of #Moderna #covid #vaccine drops from 86% to 76% in 6 months but it still remains far more effective than #Pfizer vaccine which drops from 76% to 42% in the same 6 month period pic.twitter.com/AeFcQoRZmp— Riaz Haq (@haqsmusings) August 17, 2021
“The increased risk of breakthrough in this analysis quantifies the impact of waning immunity,” Hoge said, adding that the falloff in protection comes, “between the median follow-up time of 8 months and 13 months since first dose. The Company believes this adds to evidence of potential benefit of a booster dose.”
Hoge added that while the findings haven’t made it through the peer review process yet they have been made available publicly.
While Moderna believes that a booster shot may be needed to supplement its initial doses, the company hasn’t yet completed its findings which would still require further trials before it would be approved by the FDA.
Hoge said data from its booster studies shows the vaccine could increase neutralizing antibodies to levels even higher than were seen after the second dose.
He said, “We believe this will reduce COVID-19 cases. We also believe that a third dose of mRNA-1273 has a chance of significantly extending immunity throughout much of next year as we attempt to end the pandemic.”
The data shows there were 88 cases of individuals who were infected after receiving the vaccine “recently”. That’s a rate of 49 positive cases per 1,000 individuals and 162 infections in those individuals who were vaccinated “less recently” showing an increased rate of 77.1 cases per 1,000 individuals.
Moreover, the new study shows that individuals taking the Moderna vaccine had a 36% difference in the rate of breakthrough infections after roughly 13 months compared to those individuals vaccinated roughly 8 months ago.
Another independent report published by the journal Nature Medicine found a similar outcome, after individuals were vaccinated by the Moderna vaccine, their rate of protection declined roughly after 6-months
Hoge said on the call he estimates that they would be able to boost the immunity of more than half a million people in the fall and winter months, but admits that this is only a preliminary estimate. Moderna said there was a trend toward a lower rate of severe cases among the more recently vaccinated, although the finding was not statistically significant.
In yet another study released on Wednesday conducted by Kaiser Permanente Southern California Health System, shows that the Moderna vaccine performs well against the new Delta variant.
Researchers compared data on more than 352,000 people who got two doses of the Moderna vaccine with the same number of unvaccinated individuals and found the Moderna vaccine was 87% effective at preventing a COVID-19 diagnosis. It was 96% effective at preventing hospitalization, which again shows that the initial performance of the vaccine is strong, but only during the first 6 to 8 months.